about
Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosisManagement of the critically ill patient with cirrhosis: A multidisciplinary perspective.Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management.A prognostic model for predicting survival in cirrhosis with ascites.Genomic and functional characterization of stellate cells isolated from human cirrhotic livers.Hepatorenal syndrome.Transcriptome analysis identifies TNF superfamily receptors as potential therapeutic targets in alcoholic hepatitis.CCL20 mediates lipopolysaccharide induced liver injury and is a potential driver of inflammation and fibrosis in alcoholic hepatitisHepatorenal syndrome in cirrhosis: pathogenesis and treatment.Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study.Management of cirrhosis and ascites.MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation.Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club.Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis.Therapy insight: Management of hepatorenal syndrome.What's new in the treatment of ascites and spontaneous bacterial peritonitis.Review article: albumin for circulatory support in patients with cirrhosis.The biliary epithelium gives rise to liver progenitor cellsResistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cellsKinase analysis in alcoholic hepatitis identifies p90RSK as a potential mediator of liver fibrogenesisLiver fibrogenesis: a new role for the renin-angiotensin system.Hyponatremia in cirrhosis: clinical features and management.Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome.Characteristics, Diagnosis and Prognosis of Acute-on-Chronic Liver Failure in Cirrhosis Associated to Hepatitis B.Arginine vasopressin induces contraction and stimulates growth of cultured human hepatic stellate cells.Nitric oxide synthase (NOS) inhibition for one week improves renal sodium and water excretion in cirrhotic rats with ascites.Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis CReport of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation.A histologic scoring system for prognosis of patients with alcoholic hepatitisRenal and circulatory dysfunction in cirrhosis: current management and future perspectives.Management of patients with cirrhosis awaiting liver transplantation.Management of critically-ill cirrhotic patients.Prostaglandins and the treatment of hepatorenal syndrome in cirrhosis.Hepatorenal syndrome, MELD score and liver transplantation: an evolving issue with relevant implications for clinical practice.Acute-on chronic liver failure.Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications.Satavaptan treatment for ascites in patients with cirrhosis: a meta-analysis of effect on hepatic encephalopathy development.Results of pretransplant treatment of hepatorenal syndrome with terlipressin.Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013.
P50
Q28248518-E8E07821-C4A8-4463-89C0-BA0E5F1C89E9Q30278436-5D73C49A-4187-4280-A002-CE5B2D1CCD1AQ31166704-135A0CB6-C866-4906-B6CA-18AB409099BDQ32043348-624AB92A-C312-4396-B05C-DF5A742E20D3Q33217368-2FF1F30F-8620-4CA0-9940-72328BA35882Q33710894-74E4BACA-0472-4E14-80B7-2669E2D6FE3BQ33783707-0F024A6B-5852-421D-88F6-84DCFAFCA782Q33882408-452E1F12-B692-45F6-9FD5-41A4C4ABCD7BQ33959198-ED8885D9-125A-4D3A-B860-8DEE14DCB99DQ33961582-76286E93-B445-43B2-9426-07F26564860BQ33977520-782BF864-BCE8-4992-9192-2C642FFAA88BQ33986493-BFC9AA7F-A82A-41EE-BC6C-D2A5CBAFF7A5Q34011626-F4F19E4B-549A-43EE-8374-47B14B2C679BQ34062215-B4468DFE-65A2-4442-9946-EADAE9A8FB89Q34067237-E85D2493-91AE-417E-B753-ADC9F76C8504Q34533221-D0D948C8-5DEB-4514-B896-B48CAC4A7DABQ34770385-F33E8EF5-60CC-4696-B989-349A29BF4789Q34992534-54B49419-94B0-484D-B2B6-192C214C6F1FQ35539601-69ED7127-10D5-4B3C-BEAF-35897E3FE2C0Q35569812-6230EC3B-CF77-4292-B65D-E249D0491DC3Q35915822-34F09788-867C-4798-A285-64225E839D62Q36237603-3B3A1764-F586-44FC-9535-8107103B159CQ36639788-38EA910D-C463-4972-951A-E1F9B64724F1Q36773081-D6A8234E-9D3D-4BE6-834C-A4B8178B3BCAQ36870839-CA15974F-15A1-4263-AFEE-7FCC33B68762Q36874818-7042F7FE-4C55-44DF-AA12-FD4326C85CD8Q37377075-5089A671-18E7-4AC9-8321-3D979F17CE87Q37391823-BFBB96E8-A4BE-492E-97D2-5979BDB8869DQ37624603-26407133-98E7-42BB-9FAC-DD6361287FD8Q37710980-403019D5-A481-4E78-A919-F477677479DCQ37790014-FBD4278C-8A4C-4378-8C61-664A9EA1C875Q37824774-1DDC3540-DC83-4ED9-8A7D-FFFA07C0A3CDQ37980894-7D19C01D-41C9-4021-BD0F-492FAD8D7C35Q38006548-75724DBB-B3E0-45D5-B071-02F484247A01Q38023041-FE2800BB-E617-4B2A-AAB2-58EAFF76809BQ38023100-D4BA428F-9472-48C2-AA2B-BD437AD1BF26Q38083035-0AE9B621-030E-4725-A5F1-82EA446A3520Q38086800-519D22F3-F60D-4C1F-A39F-EA2909807EC8Q38104948-894C8B71-24DA-429C-BBBE-83760D4174EEQ38188316-AB14BBDE-06A0-4124-859A-EA56A2109A38
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Pere Ginès
@ast
Pere Ginès
@en
Pere Ginès
@es
Pere Ginès
@nl
Pere Ginès
@sl
type
label
Pere Ginès
@ast
Pere Ginès
@en
Pere Ginès
@es
Pere Ginès
@nl
Pere Ginès
@sl
prefLabel
Pere Ginès
@ast
Pere Ginès
@en
Pere Ginès
@es
Pere Ginès
@nl
Pere Ginès
@sl
P214
P244
P950
P1053
B-6646-2009
P106
P1580
P21
P213
0000 0000 4058 6641
P214
P244
n2004124220
P31
P3829
P496
0000-0003-4657-4504
P7859
lccn-n2004124220